Myoepithelial carcinoma treatment in children

A report from the TREP project

Gianni Bisogno, Arianna Tagarelli, Amalia Schiavetti, Giovanni Scarzello, Andrea Ferrari, Giovanni Cecchetto, Rita Alaggio

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Myoepithelial carcinoma (MC) of soft tissues is an aggressive tumor that rarely affects children, for whom no established treatment protocols exist. As part of the TREP (Tumori Rari in Età Pediatrica) project - an Italian network dedicated to children and adolescents with very rare tumors - we present a series of patients with MC, who were treated homogeneously and achieved a satisfactory outcome. Procedure: From 2005 to 2012, seven patients (age 0.5-9.2 years) with a diagnosis of MC were registered in the TREP study. After one patient treated with ifosfamide, cisplatin, and etoposide showed tumor shrinkage and experienced long-term disease remission, all subsequent patients were treated with the same chemotherapy regimen. All patients also received radiotherapy. Results: Initial surgical management involved a biopsy in three cases and tumor resection in 4. Response to initial chemotherapy was evaluable in four patients: two had a partial remission, one a minor response and one stable disease. Four patients received external-beam radiotherapy and three had brachytherapy. Overall, six patients are alive in first complete remission with a median follow-up of 2.5 years (0.9-5.1 years). Conclusions: Though our experience is limited to a small number of patients, our treatment strategy for patients with MC is appears clinically useful and demonstrates how cooperation within the TREP project has enabled enough data to be collected to propose treatment recommendations for pediatric patients with this very rare tumor. Pediatr Blood Cancer 2014;61:643-646.

Original languageEnglish
Pages (from-to)643-646
Number of pages4
JournalPediatric Blood and Cancer
Volume61
Issue number4
DOIs
Publication statusPublished - Apr 2014

Fingerprint

Carcinoma
Therapeutics
Neoplasms
Radiotherapy
Drug Therapy
Ifosfamide
Brachytherapy
Etoposide
Clinical Protocols
Cisplatin
Pediatrics
Biopsy

Keywords

  • Myoepithelial carcinoma
  • Rare tumors
  • TREP project

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Myoepithelial carcinoma treatment in children : A report from the TREP project. / Bisogno, Gianni; Tagarelli, Arianna; Schiavetti, Amalia; Scarzello, Giovanni; Ferrari, Andrea; Cecchetto, Giovanni; Alaggio, Rita.

In: Pediatric Blood and Cancer, Vol. 61, No. 4, 04.2014, p. 643-646.

Research output: Contribution to journalArticle

Bisogno, G, Tagarelli, A, Schiavetti, A, Scarzello, G, Ferrari, A, Cecchetto, G & Alaggio, R 2014, 'Myoepithelial carcinoma treatment in children: A report from the TREP project', Pediatric Blood and Cancer, vol. 61, no. 4, pp. 643-646. https://doi.org/10.1002/pbc.24818
Bisogno, Gianni ; Tagarelli, Arianna ; Schiavetti, Amalia ; Scarzello, Giovanni ; Ferrari, Andrea ; Cecchetto, Giovanni ; Alaggio, Rita. / Myoepithelial carcinoma treatment in children : A report from the TREP project. In: Pediatric Blood and Cancer. 2014 ; Vol. 61, No. 4. pp. 643-646.
@article{923b97f7888746b18328699d107a9847,
title = "Myoepithelial carcinoma treatment in children: A report from the TREP project",
abstract = "Background: Myoepithelial carcinoma (MC) of soft tissues is an aggressive tumor that rarely affects children, for whom no established treatment protocols exist. As part of the TREP (Tumori Rari in Et{\`a} Pediatrica) project - an Italian network dedicated to children and adolescents with very rare tumors - we present a series of patients with MC, who were treated homogeneously and achieved a satisfactory outcome. Procedure: From 2005 to 2012, seven patients (age 0.5-9.2 years) with a diagnosis of MC were registered in the TREP study. After one patient treated with ifosfamide, cisplatin, and etoposide showed tumor shrinkage and experienced long-term disease remission, all subsequent patients were treated with the same chemotherapy regimen. All patients also received radiotherapy. Results: Initial surgical management involved a biopsy in three cases and tumor resection in 4. Response to initial chemotherapy was evaluable in four patients: two had a partial remission, one a minor response and one stable disease. Four patients received external-beam radiotherapy and three had brachytherapy. Overall, six patients are alive in first complete remission with a median follow-up of 2.5 years (0.9-5.1 years). Conclusions: Though our experience is limited to a small number of patients, our treatment strategy for patients with MC is appears clinically useful and demonstrates how cooperation within the TREP project has enabled enough data to be collected to propose treatment recommendations for pediatric patients with this very rare tumor. Pediatr Blood Cancer 2014;61:643-646.",
keywords = "Myoepithelial carcinoma, Rare tumors, TREP project",
author = "Gianni Bisogno and Arianna Tagarelli and Amalia Schiavetti and Giovanni Scarzello and Andrea Ferrari and Giovanni Cecchetto and Rita Alaggio",
year = "2014",
month = "4",
doi = "10.1002/pbc.24818",
language = "English",
volume = "61",
pages = "643--646",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Myoepithelial carcinoma treatment in children

T2 - A report from the TREP project

AU - Bisogno, Gianni

AU - Tagarelli, Arianna

AU - Schiavetti, Amalia

AU - Scarzello, Giovanni

AU - Ferrari, Andrea

AU - Cecchetto, Giovanni

AU - Alaggio, Rita

PY - 2014/4

Y1 - 2014/4

N2 - Background: Myoepithelial carcinoma (MC) of soft tissues is an aggressive tumor that rarely affects children, for whom no established treatment protocols exist. As part of the TREP (Tumori Rari in Età Pediatrica) project - an Italian network dedicated to children and adolescents with very rare tumors - we present a series of patients with MC, who were treated homogeneously and achieved a satisfactory outcome. Procedure: From 2005 to 2012, seven patients (age 0.5-9.2 years) with a diagnosis of MC were registered in the TREP study. After one patient treated with ifosfamide, cisplatin, and etoposide showed tumor shrinkage and experienced long-term disease remission, all subsequent patients were treated with the same chemotherapy regimen. All patients also received radiotherapy. Results: Initial surgical management involved a biopsy in three cases and tumor resection in 4. Response to initial chemotherapy was evaluable in four patients: two had a partial remission, one a minor response and one stable disease. Four patients received external-beam radiotherapy and three had brachytherapy. Overall, six patients are alive in first complete remission with a median follow-up of 2.5 years (0.9-5.1 years). Conclusions: Though our experience is limited to a small number of patients, our treatment strategy for patients with MC is appears clinically useful and demonstrates how cooperation within the TREP project has enabled enough data to be collected to propose treatment recommendations for pediatric patients with this very rare tumor. Pediatr Blood Cancer 2014;61:643-646.

AB - Background: Myoepithelial carcinoma (MC) of soft tissues is an aggressive tumor that rarely affects children, for whom no established treatment protocols exist. As part of the TREP (Tumori Rari in Età Pediatrica) project - an Italian network dedicated to children and adolescents with very rare tumors - we present a series of patients with MC, who were treated homogeneously and achieved a satisfactory outcome. Procedure: From 2005 to 2012, seven patients (age 0.5-9.2 years) with a diagnosis of MC were registered in the TREP study. After one patient treated with ifosfamide, cisplatin, and etoposide showed tumor shrinkage and experienced long-term disease remission, all subsequent patients were treated with the same chemotherapy regimen. All patients also received radiotherapy. Results: Initial surgical management involved a biopsy in three cases and tumor resection in 4. Response to initial chemotherapy was evaluable in four patients: two had a partial remission, one a minor response and one stable disease. Four patients received external-beam radiotherapy and three had brachytherapy. Overall, six patients are alive in first complete remission with a median follow-up of 2.5 years (0.9-5.1 years). Conclusions: Though our experience is limited to a small number of patients, our treatment strategy for patients with MC is appears clinically useful and demonstrates how cooperation within the TREP project has enabled enough data to be collected to propose treatment recommendations for pediatric patients with this very rare tumor. Pediatr Blood Cancer 2014;61:643-646.

KW - Myoepithelial carcinoma

KW - Rare tumors

KW - TREP project

UR - http://www.scopus.com/inward/record.url?scp=84893436310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893436310&partnerID=8YFLogxK

U2 - 10.1002/pbc.24818

DO - 10.1002/pbc.24818

M3 - Article

VL - 61

SP - 643

EP - 646

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -